{"id":"W2515800681","doi":"10.1182/blood.v122.21.1978.1978","title":"Outcomes and Correlative Studies Of a Phase I Trial With The Oral PARP1-2 Inhibitor Veliparib In Combination With Bortezomib In Patients With Relapsed Or Refractory Multiple Myeloma","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Veliparib; Bortezomib; PARP inhibitor; Medicine; Proteasome inhibitor; Carfilzomib; Synthetic lethality; Internal medicine; Oncology; Olaparib; Multiple myeloma; PARP1; Ixazomib; Pharmacology; Cancer research; Poly ADP ribose polymerase; DNA repair; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003197782,0.0006090637,0.001330293,0.0002918112,0.0003754067,0.0009032591,0.0004596559,0.0005648047,0.001729651],"category_scores_gemma":[0.002035293,0.0002988768,0.001185929,0.0003686034,0.0004757024,0.0005090752,0.0003422391,0.001645823,0.0002688927],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008800632,"about_ca_system_score_gemma":0.0006868119,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000365081,"about_ca_topic_score_gemma":0.0006454687,"domain_scores_codex":[0.9987828,0.0006839345,0.00009501808,0.00019684,0.0001028877,0.0001385565],"domain_scores_gemma":[0.9979062,0.0005836047,0.0006546153,0.0001410303,0.0001408769,0.0005736744],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7662975,0.02093388,0.09004325,0.0006064579,0.004202302,0.0006137608,0.0003278271,0.003077771,0.02167369,0.0002861167,0.002800497,0.08913698],"study_design_scores_gemma":[0.2006067,0.604431,0.1717031,0.00009373151,0.003931724,0.0007638205,0.0001642064,0.00277547,0.008762429,0.000460018,0.006251459,0.00005630725],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941082,0.002601682,0.0002597088,0.0002497743,0.00006388563,0.0004890572,0.000671164,0.00001557005,0.001540991],"genre_scores_gemma":[0.9972574,0.0003818607,0.0002089811,0.000233295,0.0001111202,0.0003062843,0.0008951175,0.000004501543,0.0006014712],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003197782,"threshold_uncertainty_score":0.01691163,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03003685226125718,"score_gpt":0.3098216803747563,"score_spread":0.2797848281134991,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}